Baclofen

# Research Output: Baclofen

## Chemical Identity

**PubChem CID:** 2284 (verified via API)
**Molecular Formula:** C₁₀H₁₂ClNO₂ [Ref 40]
**Molecular Weight:** 213.66 g/mol [Ref 40]
**IUPAC Name:** 4-amino-3-(4-chlorophenyl)butanoic acid [Ref 40]
**Common name / systematic name:** β-(4-chlorophenyl)-γ-aminobutyric acid (these two names describe the same structure) [Ref 16]
**InChIKey:** KPYSYYIEGFHWSV-UHFFFAOYSA-N [Ref 40]
**CAS Number:** 1134-47-0 [web-retrieved; not API-verified]
**Slug / Brand:** baclofen / Lioresal (original Ciba brand)

### Discrepancies with Seed Data

1. **⚠️ FLAG — Chemical class error:** The database lists baclofen's chemical class as "Phenethylamine, Substituted phenethylamine." This is **incorrect**. Baclofen is a GABA analog (phenylbutanoic acid derivative). Its backbone is γ-aminobutyric acid (GABA) substituted with a para-chlorophenyl group at the β-carbon — structurally distinct from phenethylamines, which have a two-carbon chain from the phenyl ring to the amine. This classification should be corrected to "GABA analog / Phenylbutanoic acid derivative." [Ref 16]

2. **Missing identifiers filled:** PubChem CID (2284), molecular formula (C₁₀H₁₂ClNO₂), molecular weight (213.66), and InChIKey (KPYSYYIEGFHWSV-UHFFFAOYSA-N) were all missing from seed data and have been confirmed via the PubChem API. [Ref 40]

3. **Characterization listed as "emerging":** Baclofen is a mature, well-characterized pharmaceutical compound in clinical use since 1977. The "emerging" characterization is incorrect for a substance with >50 years of clinical use. [Ref 16]

4. **SMILES:** Not returned by PubChem API for this compound; can be retrieved by CID lookup directly.

---

## Pharmacology

### Mechanism of Action

Baclofen is the only FDA-approved selective GABA-B receptor agonist (Kent et al. 2020 [Ref 16]). The GABA-B receptor is a Class C G protein-coupled receptor (GPCR) that functions as an obligatory heterodimer composed of two subunits: GB1 and GB2 (Shaye et al. 2020 [Ref 51]; Mao et al. 2020 [Ref 52]). Baclofen binds the Venus flytrap (VFT) domain of the GB1 subunit, triggering conformational rearrangement and signaling through the GB2 subunit's coupling to Gi/o proteins (Shaye et al. 2020 [Ref 51]).

**Presynaptic effects (primary):** Baclofen activates presynaptic GABA-B receptors on primary afferent neurons and interneurons. This inhibits voltage-gated Ca²⁺ channels (particularly N- and P/Q-type), reducing calcium influx and thereby suppressing neurotransmitter release (Isaacson 1998 [Ref 53]; Takahashi et al. 1998 [Ref 54]). This reduces release of excitatory neurotransmitters including glutamate and substance P in the spinal cord, producing the muscle relaxant and antinociceptive effects [Ref 53].

**Postsynaptic effects:** Baclofen activates postsynaptic GABA-B receptors coupled to GIRK (G protein-coupled inwardly rectifying K⁺, Kir3) channels, hyperpolarizing neurons and suppressing excitability. This mechanism underlies anxiolytic and sedating properties (Luo et al. 2025 [Ref 55]).

**Dopaminergic modulation:** Baclofen reduces dopamine release in the nucleus accumbens shell via presynaptic GABA-B receptors on dopaminergic terminals, which is attenuated in animal models of schizophrenia (Ferdinand et al. 2021 [Ref 56]).

**Cough reflex:** Baclofen inhibits the cough reflex via central GABA-B receptor agonism; peripheral GABA-B agonists (e.g. 3-APPi) have a separate peripheral site of action (Bolser et al. 1994 [Ref 57]; Badri et al. 2021 [Ref 23]).

**Esophageal effects:** Baclofen inhibits transient lower esophageal sphincter relaxations (TLESRs) by activating vagal GABA-B receptors, reducing gastroesophageal reflux (Warren & Davis 2015 [Ref 22]; Scarpellini et al. 2016 [Ref 58]).

**Timing note:** Baclofen received FDA approval (1977) **before** its receptor, GABA-B, was formally characterized and named (~1980 by Norman Bowery) (Kent et al. 2020 [Ref 16]). The drug's mechanism was therefore elucidated retrospectively.

### Receptor Binding

No published Ki or EC50 values at human GABA-B receptor were returned via API-accessible databases. Published literature consistently describes baclofen as a selective, full GABA-B receptor agonist. The R-enantiomer carries essentially all GABA-B agonist activity; the S-enantiomer is pharmacologically inactive at GABA-B receptors (Kent et al. 2020 [Ref 16]; Lal et al. 2009 [Ref 4]).

⚠️ **FLAG:** Specific Ki/EC50 values for baclofen at human GABA-B receptor are not available from sources accessed. This is a gap in the binding affinity data.

### Stereochemistry

Baclofen is marketed and used clinically as a **racemate** (equal mixture of R- and S-enantiomers). The **R-enantiomer** (arbaclofen) is the pharmacologically active isomer at GABA-B receptors. The S-enantiomer undergoes hepatic metabolism to S-M1, while the R-enantiomer undergoes little metabolic transformation (Lal et al. 2009 [Ref 4]). Arbaclofen placarbil (STX209) is a prodrug of the R-enantiomer with improved intestinal absorption characteristics. Clinical trials of arbaclofen for autism spectrum disorder and fragile X syndrome have used the pure R-enantiomer (Kent et al. 2020 [Ref 16]).

### Pharmacokinetics

| Parameter | Value | Source |
|---|---|---|
| Bioavailability (oral) | 70–85% | StatPearls [Ref 40] |
| Tmax | 1.0–2.79 h (typically ~2 h) | Wuis et al. 1990 [Ref 31]; StatPearls [Ref 40] |
| Half-life (plasma, oral) | ~3.5 h | StatPearls [Ref 40] |
| Half-life (CSF, intrathecal) | ~1.5 h | StatPearls [Ref 40] |
| Protein binding | 30–35% | Wuis et al. 1990 [Ref 31] |
| Volume of distribution | ~59 L (Varea/F) | Kochak et al. 1985 [Ref 2] |
| Total body clearance | ~175–180 mL/min | Kochak et al. 1985 [Ref 2]; Wuis et al. 1990 [Ref 31] |
| Renal clearance | ~103 mL/min | Kochak et al. 1985 [Ref 2] |
| Renal excretion (unchanged) | 65–70% | Wuis et al. 1990 [Ref 31]; Salim et al. 2018 [Ref 17] |
| Hepatic metabolism | Minor | Salim et al. 2018 [Ref 17] |
| Effect of food | None significant | Peterson et al. 1985 [Ref 3] |

**Absorption mechanism:** Baclofen has a specialized carrier-mediated transport system in the small intestine (particularly the mid-segment) obeying Michaelis-Menten kinetics (Merino et al. 1989 [Ref 1]). Colonic absorption is negligible, which limits the viability of extended-release formulations beyond 8 hours. This narrow absorption window means standard sustained-release formulations >8 hours are pharmacokinetically problematic (Merino et al. 1989 [Ref 1]).

**Renal function:** Because ~65–70% of baclofen is excreted unchanged by the kidneys, patients with renal impairment are at dramatically increased risk of drug accumulation and toxicity, even at standard doses (Salim et al. 2018 [Ref 17]; El-Husseini et al. 2011 [Ref 30]). Apparent renal clearance equals creatinine clearance, making CrCl a useful proxy (Wuis et al. 1990 [Ref 31]).

**High-dose PK:** At doses substantially exceeding 80 mg/day, time-to-peak plasma levels and half-lives may be longer than standard parameters, and gradual drug accumulation has been observed, likely reflecting impaired clearance (Aisen et al. 1992 [Ref 32]).

---

## History

Baclofen was first synthesized in **1962** by Swiss chemist **Heinrich Keberle** at Ciba-Geigy (Basel, Switzerland), following a scientific conference organized by Wilhelm Feldberg at the Royal Society in London. Keberle's goal was to create a more lipophilic, blood-brain-barrier-penetrant analog of γ-aminobutyric acid (GABA) for the potential treatment of epilepsy (Kent et al. 2020 [Ref 16]; [Ref 26]).

Early preclinical and clinical investigations revealed that baclofen was **not effective for epilepsy**. However, a pivotal observation emerged during these early trials: baclofen markedly reduced muscle spasticity in patients who had this comorbidity. Development focus shifted entirely to spasticity ([Ref 26]).

The **U.S. FDA approved baclofen in 1977** under the brand name Lioresal (Ciba-Geigy) for the treatment of spasticity related to multiple sclerosis, spinal cord injuries, and other spinal cord pathologies. Crucially, this approval predated the formal characterization of the GABA-B receptor, which was named and characterized ~1980 by Norman Bowery. Baclofen thus became an approved drug before its molecular target was understood (Kent et al. 2020 [Ref 16]).

**Intrathecal delivery:** Penn and Kroin developed intrathecal baclofen delivery in the early 1980s for patients with severe spasticity unresponsive to oral therapy. Intrathecal baclofen therapy has been in clinical use since approximately 1982 (Kaye et al. 2025 [Ref 29]).

**Alcohol use disorder:** In 2005, French-American cardiologist **Olivier Ameisen** published a self-case report describing complete suppression of alcohol dependence symptoms using very high-dose baclofen (up to 270 mg/day) (Ameisen 2005 [Ref 18]). This report, later elaborated in a widely-read book ("Le Dernier Verre," 2008), triggered extensive clinical research and a social movement in France advocating baclofen for AUD. In **March 2014**, French health authority ANSM granted a "Temporary Recommendation for Use" (TRU) allowing physicians to prescribe baclofen for AUD at doses up to 300 mg/day (de Beaurepaire & Rolland 2022 [Ref 33]). In **June 2020**, Ethypharm's brand Baclocur (baclofen) received formal French marketing authorization for AUD, making France the **first country to specifically approve baclofen for alcohol use disorder**. The French approval caps the dose at 80 mg/day [Ref 41].

---

## Subjective Effects

Baclofen's therapeutic dose range (10–80 mg/day for spasticity) produces predominantly:

- **Muscle relaxation:** Primary therapeutic effect; reduction of spastic motor tone and involuntary spasms (Dietz et al. 2023 [Ref 19])
- **Sedation:** Common dose-dependent adverse effect documented across spasticity trials; described as "asthenia" (weakness/fatigue) in comparative trials (Agarwal et al. 2017 [Ref 20])
- **Dizziness:** Reported at therapeutic doses; related to postural hypotension and CNS effects
- **Nausea:** Common, particularly at dose initiation
- **Motor control impairment:** At therapeutic doses; a dose-limiting concern in ambulatory patients

At **higher doses** used in AUD trials (30–270 mg/day):
- **Anxiety suppression / anxiolysis:** Documented in clinical trials and fMRI studies; baclofen attenuates insula and inferior frontal gyrus activation during anticipatory threat (Morley et al. 2021 [Ref 5])
- **Craving reduction:** Reduced alcohol cue-elicited activation in OFC, amygdala, and VTA in fMRI studies; decreased functional connectivity in reward circuits (Beck et al. 2018 [Ref 36])
- **Reduction in compulsive craving:** Ameisen's self-reports described "indifference" to alcohol — a qualitatively different state from mere suppression of drinking (Ameisen 2005 [Ref 18])
- **Euphoria / disinhibition:** The Cochrane review notes that baclofen "rarely produces euphoria or other pleasant effects, or craving for the drug" in clinical settings (Liu & Wang 2019 [Ref 15]). This is a noted advantage over benzodiazepines for AUD contexts.
- **HPA axis modulation:** Baclofen reduces cortisol stress response, suggesting endocrinological anxiolysis (Logge et al. 2023 [Ref 49])
- **Cognitive fatigue / amnesia:** Reported at higher doses; benzodiazepine-like cognitive blunting at supratherapeutic levels
- **Thought deceleration / sedation:** Common at high doses

**At toxic doses (>200 mg acute in single ingestion):**
- Deep CNS depression, loss of consciousness, respiratory failure, coma (Zari Meidani et al. 2023 [Ref 7])
- Can produce EEG-confirmed burst suppression and mimic brain death clinically (Koker et al. 2020 [Ref 9])

**Recreational/non-medical use:** Limited published data on recreational use patterns. The Cochrane review notes baclofen has low euphoriant potential compared to benzodiazepines (Liu & Wang 2019 [Ref 15]). No formal human abuse liability studies were found via API.

---

## Safety & Toxicity

### Acute Toxicity

Acute baclofen overdose constitutes a medical emergency characterized by:
- **Profound CNS depression** (loss of consciousness, GCS decline to 3 in extreme cases)
- **Respiratory depression / failure**
- **Bradycardia**, hypotension, hypothermia
- **Seizures** (paradoxical, seen both acutely and during withdrawal)
- **Fixed dilated pupils** (mimicking brain death) (Koker et al. 2020 [Ref 9])
- **Cardiac arrhythmias:** Supraventricular tachyarrhythmia documented; cardiac monitoring warranted in acute overdose (Roberge et al. 1994 [Ref 11])
- **Rare respiratory complications:** Atelectasis, pneumomediastinum (Zari Meidani et al. 2023 [Ref 7])

Case reports document toxicity at **>200 mg in a single ingestion** (Zari Meidani et al. 2023 [Ref 7]). A pediatric patient (15 years) who ingested an unstated overdose presented with GCS 3 and fixed dilated pupils but fully recovered with supportive care by day 2 (Koker et al. 2020 [Ref 9]).

**Treatment:** Supportive care is the mainstay. Hemodialysis can accelerate elimination in patients with **renal impairment** (given renal-dominant excretion) but offers **negligible benefit** in patients with normal kidney function — in one pediatric overdose case, hemodialysis removal was negligible compared to intact renal excretion (Lee et al. 2021 [Ref 8]; Brvar et al. 2007 [Ref 10]).

**⚠️ FLAG — LD50:** No LD50 data in humans was identified in the literature searched. Animal LD50 data not retrieved. This is a gap. Toxicity thresholds appear to be individual and context-dependent.

### Toxicity in Renal Impairment

Patients with renal impairment are at dramatically elevated risk for baclofen toxicity at normal doses. Baclofen half-life is prolonged, AUC increases, and CNS toxicity manifests with confusion, encephalopathy, and coma even at therapeutic doses (Salim et al. 2018 [Ref 17]; El-Husseini et al. 2011 [Ref 30]; AlShaqaq et al. 2026 [Ref 59]). This is a well-documented drug safety issue that has prompted calls for improved labeling.

### Chronic Toxicity

No specific chronic organ toxicity data was identified. Baclofen is notably **hepatically safe** and has been used in patients with liver cirrhosis (Addolorato et al. 2007 [Ref 42]) — a significant advantage over most GABAergic drugs that are hepatically metabolized.

### Neurotoxicity

Baclofen can cause a **metabolic encephalopathy** with characteristic EEG changes. Importantly, concomitant benzodiazepine administration can **exacerbate** baclofen neurotoxicity (Triplett et al. 2019 [Ref 24]).

### Respiratory

Central sleep apnea has been documented at **low doses** of baclofen (10 mg), indicating risk even at standard therapeutic doses for susceptible patients (Luo et al. 2025 [Ref 28]).

### Pregnancy

Baclofen is classified as **Category C** (risk cannot be ruled out) based on animal studies. One comparative study of 134 women exposed to baclofen in early pregnancy vs. 400 controls showed an **increased risk of major malformations** (Prescrire International 2015 [Ref 44]). Neonatal withdrawal syndrome has been documented following intrauterine exposure (Mousigian et al. 2022 [Ref 45]; Duncan & Devlin 2013 [Ref 47]).

---

## Harm Reduction

1. **Avoid abrupt discontinuation:** Withdrawal syndrome (see below) can be life-threatening. Baclofen should always be tapered gradually, not stopped suddenly.
2. **Renal function monitoring:** Essential in any patient receiving baclofen. Dose adjustment required in renal impairment; avoid in severe renal failure.
3. **CNS depressant combinations:** Baclofen + alcohol, opioids, or benzodiazepines carries risk of additive/synergistic CNS and respiratory depression. The combinations listed in the database (alcohol, GHB, GBL, methaqualone) as "lethal" reflect this pharmacodynamic interaction.
4. **Opioid interaction:** Particularly dangerous — case series document life-threatening CNS depression from opioid + intrathecal baclofen (van Dijk et al. 2024 [Ref 21]).
5. **Dose titration:** In clinical practice, baclofen is always started at low doses (5 mg TID) and titrated slowly to minimize sedation and CNS adverse effects.
6. **Benzodiazepine interaction:** Avoid combining; benzodiazepines can exacerbate baclofen neurotoxicity beyond additive CNS depression (Triplett et al. 2019 [Ref 24]).
7. **Pregnancy:** Should not be used unless clearly necessary; neonatal monitoring for withdrawal recommended if exposed in utero (Mousigian et al. 2022 [Ref 45]).
8. **Emergency:** Acute overdose is a medical emergency; support airway/breathing; do not administer flumazenil (no reversal agent exists for baclofen).

---

## Tolerance & Dependence

### Tolerance

**Tolerance development:** Documented within "a couple of days of continuous use" per the seed data, which aligns with the general pharmacology of GABAergic agents. Published literature confirms physical dependence formation with regular use (Iqbal et al. 2026 [Ref 14]).

### Dependence

Baclofen is **moderately physically and psychologically addictive** (consistent with seed data). The Cochrane review notes that baclofen rarely produces euphoria or drug craving, which may reduce psychological dependence liability compared to benzodiazepines. However, physical dependence is well-documented (Liu & Wang 2019 [Ref 15]).

### Withdrawal Syndrome

Abrupt discontinuation of baclofen produces a clinically significant withdrawal syndrome characterized by:
- **Hyperthermia / fever**
- **Tachycardia**
- **Severe psychomotor agitation**
- **Seizures**
- **Delirium**
- **Rebound spasticity** (in patients being treated for spasticity)

This syndrome is documented for both oral and intrathecal baclofen. The systematic review of baclofen toxicity and withdrawal (Iqbal et al. 2026 [Ref 14]) comprehensively characterizes these presentations. A case report documents combined baclofen/tizanidine withdrawal with overlapping features including hypotonia, fever, tachycardia, and worsening agitation within 24 hours of last dose (Bonomi et al. 2026 [Ref 25]).

**Management of withdrawal:** Reinstatement of baclofen, benzodiazepines (with caution given interaction risk), and dexmedetomidine have been used. Gradual taper is strongly preferred.

**Neonatal withdrawal:** Documented in infants exposed in utero to maternal baclofen; can include seizures (Duncan & Devlin 2013 [Ref 47]; Mousigian et al. 2022 [Ref 45]).

**Cross-tolerance:** Cross-tolerance with other GABAergic substances (especially GABA-B active agents) is expected. The database lists GABA cross-tolerance, which is consistent with pharmacological class.

**Full tolerance reset:** The seed data reports 10.5 days for full reset; this is not confirmed by a specific published source found during research. ⚠️ **FLAG for editorial review.**

---

## Interactions

All interactions listed in the brief's seed data (alcohol, GHB, GBL, methaqualone — "lethal") reflect **pharmacodynamic synergy** at CNS depressant mechanisms. These are confirmed as severe interactions:

### Alcohol
Synergistic CNS depression. Both baclofen and ethanol act via GABA-B pathways (Vengeliene et al. 2008 [Ref 60]). Paradoxically, baclofen is used clinically to reduce alcohol craving — but co-ingestion of therapeutic or supratherapeutic baclofen with significant alcohol intake potentiates sedation and respiratory depression to potentially lethal degree. Severity: **lethal** (confirmed as serious interaction in pharmacology literature).

### GHB / GBL
GHB is an endogenous GABA-B agonist and GBL is its prodrug. Combination with baclofen produces near-additive GABA-B receptor activation, synergistic CNS and respiratory depression. Severity: **lethal** (pharmacodynamically plausible; referenced in GHB toxicology literature [Ref 61]).

### Opioids
Potentially lethal CNS and respiratory depression via independent but additive mechanisms (opioid receptors + GABA-B). Case series document life-threatening episodes with intrathecal baclofen + opioids (van Dijk et al. 2024 [Ref 21]).

### Benzodiazepines
Additive CNS depression; benzodiazepines specifically exacerbate baclofen neurotoxicity (Triplett et al. 2019 [Ref 24]). Not listed as "lethal" in seed data but should be treated as a serious interaction.

### Methaqualone
Also a CNS depressant (GABA-A, glycine receptor modulator). Combination with baclofen produces additive/synergistic CNS depression. Severity: **lethal** (seed data; pharmacodynamically plausible).

### CYP Interactions
No significant CYP enzyme interactions identified. Baclofen undergoes minimal hepatic metabolism; drug-drug interactions via CYP pathways are not expected to be clinically significant. ⚠️ **FLAG:** No specific published CYP inhibition/induction data found; absence of significant CYP interaction assumed based on predominantly renal elimination.

---

## Legal Status

| Jurisdiction | Status |
|---|---|
| **United States** | Prescription-only; NOT a DEA scheduled substance; FDA approved 1977 for spasticity |
| **United Kingdom** | Prescription-only medicine (POM); not a controlled drug under Misuse of Drugs Act |
| **European Union** | Prescription-only in all member states; France approved Baclocur (Ethypharm) for AUD in June 2020 with max dose 80 mg/day |
| **France** | First country with specific AUD indication (Baclocur, 2020); preceded by TRU 2014–2017 (up to 300 mg/d) |
| **Canada** | Prescription-only; no controlled substance scheduling |
| **Australia** | TGA approved; prescription-only |

Baclofen is on the WHO Essential Medicines List (for spasticity management). No analog act applicability identified — baclofen is a named, approved pharmaceutical in all major jurisdictions.

---

## Clinical Trials

### Key Completed Trials

| Trial | NCT ID | Phase | Condition | Outcome |
|---|---|---|---|---|
| **BACLAD** | NCT01266655 | RCT | Alcohol dependence | Individually titrated 30–270 mg/d: 68.2% vs 23.8% abstinence (p=0.014) (Müller et al. 2015 [Ref 34]) |
| **ALPADIR** | — | RCT | Alcohol dependence | Baclofen 180 mg/d vs placebo for abstinence maintenance (Reynaud et al. 2017 [Ref 35]) |
| **Addolorato 2007** | — | RCT | AUD + liver cirrhosis | Baclofen safe and superior to placebo in cirrhotic patients (Addolorato et al. 2007 [Ref 42]) |
| **Arbaclofen MS** | NCT01743651 | Phase 3 | MS spasticity | Arbaclofen (R-baclofen) vs placebo; completed |
| **French TRU cohort** | — | Observational | AUD | 5,550 subjects; doses >80 mg/d; significant ↓ alcohol consumption and craving (de Beaurepaire & Rolland 2022 [Ref 33]) |

### Active / Recruiting Trials (as of 2026)

| NCT ID | Phase | Condition | Sponsor |
|---|---|---|---|
| NCT03293017 | Phase 4 | Alcohol withdrawal | UZ Brussel |
| NCT04679142 | — | AUD safety surveillance (Baclocur) | Ethypharm, France |
| NCT03034408 | Phase 2 | AUD (nalmefene vs baclofen) | Prof. Zullino |
| NCT06606574 | — | Pediatric dystonia (ITB) | Baylor College of Medicine |
| NCT06564714 | Phase 4 | Acute spasticity post-SCI | CIUSSS Montreal |

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief. No community feedback items to investigate or report.

---

## Gaps & Flags

### Safety-Critical Flags

1. **⚠️ Chemical class error in seed data:** Baclofen is listed as "Phenethylamine, Substituted phenethylamine" — this is pharmacologically incorrect. Baclofen is a GABA analog (β-substituted GABA, phenylbutanoic acid derivative). The generation agent must correct this. [Ref 16, Ref 40]

2. **⚠️ Characterization as "emerging":** Baclofen has been FDA-approved since 1977 and has over 60 years of clinical use. The "emerging" characterization in the seed data is incorrect and should be changed to "established" or similar.

3. **⚠️ LD50 / Therapeutic index data absent:** No human LD50 data was found. The toxic single-ingestion dose appears to be >200 mg based on case reports (Zari Meidani et al. 2023 [Ref 7]), but no formal safety-critical threshold has been established in controlled studies.

4. **⚠️ Ki/EC50 binding affinity data absent:** No published Ki or EC50 values at human GABA-B receptors were found in accessible literature. Baclofen is described qualitatively as a selective, full GABA-B agonist.

5. **⚠️ Tolerance reset period (10.5 days):** The seed data states a "full tolerance reset" of 10.5 days. This specific figure was not confirmed by a published source in the searches conducted. Flagged for editorial verification.

6. **⚠️ CYP interaction data absent:** No published data on CYP enzyme involvement found. Presumed minimal based on primarily renal elimination.

### Data Gaps

- **Specific Ki/EC50 binding data** at GABA-B not found in accessible literature
- **SMILES string** not returned by PubChem API (should be retrievable from CID 2284 directly)
- **Recreational/non-medical subjective effects data** is sparse — most published descriptions come from therapeutic contexts; recreational use literature is limited
- **LD50 (animal or human)** not found
- **Australia/Canada-specific scheduling history** not found beyond confirmation of prescription-only status
- **Specific CYP enzymes involved in minor hepatic metabolism** not identified in searched literature
- **Baclofen melting point and aqueous solubility** not retrieved

### Notes on Seed Data Dose/Duration

The seed dose and duration data appear clinically reasonable based on the literature:
- Dose ranges (threshold 5 mg, light 10–20 mg, common 20–50 mg, strong 50–100 mg, heavy 100+ mg) align with therapeutic dosing in spasticity (5–80 mg/day) and AUD trials (up to 300 mg/day in French TRU)
- Duration data (onset 30–75 min, Tmax-effect ~2 h, total 8–14 h) is broadly consistent with PK half-life of 3.5 h and typical dosing intervals in clinical practice
- The aftereffects of 6–12 h appear plausible but not confirmed by a specific published study found in this research

---

## Additional Off-Label Uses Documented in Literature

1. **Gastroesophageal reflux disease (GERD):** Reduces TLESRs; used as add-on for PPI-refractory GERD (Warren & Davis 2015 [Ref 22]; Scarpellini et al. 2016 [Ref 58])
2. **Rumination syndrome / supra-gastric belching:** RCT-level evidence (Pauwels et al. 2018 [Ref 50])
3. **Intractable hiccups:** 91% cure rate in single-arm trial in chemotherapy patients (Mei et al. 2023 [Ref 46])
4. **Chronic cough:** GABA-B agonism inhibits cough reflex centrally (Badri et al. 2021 [Ref 23])
5. **Opioid withdrawal facilitation:** Used as adjunct in detoxification protocols (Akhondzadeh et al. 2000 [Ref 62])
6. **Anxiety disorders:** Anxiolytic properties documented in clinical fMRI studies (Morley et al. 2021 [Ref 5])
7. **Neuropathic pain:** Used in multimodal pain management, though data is limited